(Q51741520)

English

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.

scientific article published on 25 August 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

0 references

author name string

Masayuki Kamatari

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Shiro Koto

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Nobuhiro Ozawa

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Chie Urao

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Yumiko Suzuki

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Eri Akasaka

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Kae Yanagimoto

7

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Kazumi Sakota

8

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

publication date

25 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Journal of Bone and Mineral Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

25

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

302-309

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-007-0768-6

21 January 2018

A pharmacokinetic analysis program (multi) for microcomputer

1 reference

https://api.crossref.org/works/10.1007%2FS00774-007-0768-6

21 January 2018

Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00774-007-0768-6

21 January 2018

Compliance with pharmacologic therapy for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance with osteoporosis medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologic therapy for the treatment and prevention of osteoporosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality-of-life assessment in osteoporosis: health-status and preference-based measures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence with weekly alendronate therapy among postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies of the oral bioavailability of alendronate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of dosing regimen on the pharmacokinetics of risedronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug insight: Bisphosphonates for postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance of osteoporotic patients with different treatment regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability and compliance with risedronate in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance with treatment in osteoporosis patients--an ongoing problem

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral bisphosphonates: A review of clinical use in patients with bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17704995

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00774-007-0768-6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/17704995

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51741520&oldid=2211154815"